Rapamycin

An mTOR inhibitor FDA-approved for transplant rejection that has emerged as the most consistently replicated pharmacologic lifespan-extending agent in mammals.

Also known as: Sirolimus, Rapamune, AY-22989

Regulatory Status

FDA-Approved

Classification date: 1999-09-15

Compounding: Not currently available for compounding

Evidence Summary

Strong50 human studies published

Key Studies

How It Works

Rapamycin binds to FKBP12 and inhibits mTORC1, a master regulator of cell growth, protein synthesis, and autophagy. By suppressing mTORC1, rapamycin upregulates autophagy — the cellular recycling process that clears damaged organelles and misfolded proteins. In preclinical models it has extended lifespan across yeast, worms, flies, and mice, and low-dose intermittent protocols are being investigated in humans for age-related diseases and immune rejuvenation.

Common Applications

Organ transplant rejection prevention (FDA-approved)Longevity and anti-aging research protocolsAutophagy enhancementImmune modulation and rejuvenation

Safety & Considerations

Chronic high-dose use causes immunosuppression, hyperlipidemia, impaired wound healing, and insulin resistance. Low-dose intermittent (weekly) protocols appear better tolerated and may paradoxically enhance immune function. Regular monitoring of lipids, glucose, and CBC is essential. Not appropriate for immunocompromised individuals. Drug interactions with CYP3A4 inhibitors and inducers are clinically significant.

Available Through Our Network

This peptide is available through our partner pharmacies with a valid prescription.

Coming Soon →

Regulatory classifications can change rapidly. The information shown here was last verified on 1999-09-15. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.